Obsidian Therapeutics, Inc.
Research Obsidian Therapeutics, Inc. (OBX) on Bullrun: market cap USD 1.31M, P/E 0.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOBX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.31M
- P/E0.1
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 19.63M
- Free cash flow-USD 22.01M
Valuation Snapshot
latest market cap is USD 1.31M; P/E is 0.1.
Peer valuation comparison
Latest P/E is 0.07x versus a Healthcare sector median of 21.74x (99.7% below).
Latest P/E is 0.07x versus a United States median of 23.81x (99.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 100.61M | -USD 90.47M | n/a | -1.63 | USD 40.41M | USD 4.28M | -USD 266.04M |
| FY2024 | USD 0 | -USD 83.11M | -USD 75.78M | n/a | -1.35 | USD 49.76M | USD 6.81M | -USD 174.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 1.31M | 0.1 | n/a | n/a |
About Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Obsidian Therapeutics, Inc.'s market cap?
Obsidian Therapeutics, Inc.'s market capitalization is USD 1.31M.
What is Obsidian Therapeutics, Inc.'s P/E ratio?
Obsidian Therapeutics, Inc.'s price-to-earnings (P/E) ratio is 0.1.
What does Obsidian Therapeutics, Inc. do?
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.